---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-160347"
form_type: "8-K"
ticker: "TYRA"
cik: "0001863127"
company_name: "Tyra Biosciences, Inc."
filed_at: "2026-04-17T23:59:59+00:00"
generated_at: "2026-05-15T05:35:17.027082+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Tyra Biosciences expands board to ten, appoints Habib J. Dable as Class II director

## Summary
- Board increased from nine to ten members; Dable appointed effective April 16, 2026, with term expiring at 2026 annual meeting.
- Dable previously President & CEO of Acceleron Pharma (acquired by Merck in 2021) and advisor at RA Capital since April 2022.
- Received option to purchase 44,400 shares vesting equally over 36 months; cash compensation per Non-Employee Director Program.
- Board determined Dable is independent under Nasdaq listing requirements.

## SEC filing metadata
- accession: 0001193125-26-160347
- form_type: 8-K
- ticker: TYRA
- cik: 0001863127
- company_name: Tyra Biosciences, Inc.
- filed_at: 2026-04-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1863127/000119312526160347/0001193125-26-160347-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1863127/000119312526160347/d17006d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-160347
- JSON: https://secwatch.observer/filing/0001193125-26-160347.json
- Plain text: https://secwatch.observer/filing/0001193125-26-160347.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.